Details for Patent: 9,682,080

Which drugs does patent 9,682,080 protect, and when does it expire?

Patent 9,682,080 protects AQVESME and PYRUKYND and is included in one NDA.

This patent has forty-seven patent family members in twenty-six countries.

Summary for Patent: 9,682,080

Title:	Pyruvate kinase activators for use in therapy
Abstract:	Described herein are methods for using compounds that activate pyruvate kinase.
Inventor(s):	Shin-San Michael Su
Assignee:	Agios Pharmaceuticals Inc
Application Number:	US14/886,750
Patent Claim Types: see list of patent claims	Use;

Drugs Protected by US Patent 9,682,080

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Agios Pharms Inc	AQVESME	mitapivat sulfate	TABLET;ORAL	216196-004	Dec 23, 2025		RX	Yes	Yes						METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF ANEMIA IN ADULTS WITH ALPHA OR BETA THALASSEMIA
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-001	Feb 17, 2022		RX	Yes	No						METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-002	Feb 17, 2022		RX	Yes	No						METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY
Agios Pharms Inc	PYRUKYND	mitapivat sulfate	TABLET;ORAL	216196-003	Feb 17, 2022		RX	Yes	Yes						METHOD OF USING A PYRUVATE KINASE ACTIVATOR FOR THE TREATMENT OF HEMOLYTIC ANEMIA IN ADULTS WITH PYRUVATE KINASE (PK) DEFICIENCY

International Family Members for US Patent 9,682,080

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2012250688
Australia	2017221860
Australia	2020200700
Brazil	112013028422